1-9 of 9
William R. Sellers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA001: Exploiting pathway activation as a new form of synthetic lethality

William R. Sellers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6_Supplement): IA001.
https://doi.org/10.1158/1538-8514.SYNTHLETH24-IA001
Published: 10 June 2024
View article titled, Abstract IA001: Exploiting pathway activation as a new form of synthetic lethality
Journal Articles

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Heiko S. Schadt, Philippe Couttet, Armin Wolf, Youzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Murakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William R. Sellers, Diana Graus Porta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2194–2206.
https://doi.org/10.1158/1535-7163.MCT-18-1291
Published: 02 December 2019
View article titled, FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Open the PDF for FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells

Thomas Horn, Stéphane Ferretti, Nicolas Ebel, Angela Tam, Samuel Ho, Fred Harbinski, Ali Farsidjani, Matthew Zubrowski, Ensar Halilovic, Erick Morris, William R. Sellers, Robert Schlegel, Jens Wuerthner, Levi A. Garraway, Sébastien Jeay, Joel Greshock, Giordano Caponigro, Joseph Lehár
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-B04.
https://doi.org/10.1158/1535-7163.TARG-15-LB-B04
Published: 01 December 2015
View article titled, Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells
Journal Articles

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (5): 1117–1129.
https://doi.org/10.1158/1535-7163.MCT-13-0865
Published: 05 May 2014
View article titled, Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Open the PDF for Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Saskia M. Brachmann, Julia Kleylein-Sohn, Swann Gaulis, Audrey Kauffmann, Marcel J.J. Blommers, Malika Kazic-Legueux, Laurent Laborde, Marc Hattenberger, Fabian Stauffer, Juliane Vaxelaire, Vincent Romanet, Chrystèle Henry, Masato Murakami, Daniel Alexander Guthy, Dario Sterker, Sebastian Bergling, Christopher Wilson, Thomas Brümmendorf, Christine Fritsch, Carlos Garcia-Echeverria, William R. Sellers, Francesco Hofmann, Sauveur-Michel Maira
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1747–1757.
https://doi.org/10.1158/1535-7163.MCT-11-1021
Published: 08 August 2012
View article titled, Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Open the PDF for Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations in another window
Includes: Supplementary data
Journal Articles

The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

Daniel L. Menezes, Pietro Taverna, Michael R. Jensen, Tinya Abrams, Darrin Stuart, Guoying Karen Yu, David Duhl, Timothy Machajewski, William R. Sellers, Nancy K. Pryer, Zhenhai Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 730–739.
https://doi.org/10.1158/1535-7163.MCT-11-0667
Published: 06 March 2012
View article titled, The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew Burger, Mark Knapp, Dario Sterker, Christian Schnell, Daniel Guthy, Tobi Nagel, Marion Wiesmann, Saskia Brachmann, Christine Fritsch, Marion Dorsch, Patrick Chène, Kevin Shoemaker, Alain De Pover, Daniel Menezes, Georg Martiny-Baron, Doriano Fabbro, Christopher J. Wilson, Robert Schlegel, Francesco Hofmann, Carlos García-Echeverría, William R. Sellers, Charles F. Voliva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 317–328.
https://doi.org/10.1158/1535-7163.MCT-11-0474
Published: 08 February 2012
View article titled, Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Open the PDF for Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor in another window
Includes: Supplementary data
Journal Articles

Abstract C193: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a novel orally bioavailable, selective, and potent FGFR inhibitor.

Diana Graus Porta, Vito Guagnano, Yao Yao, Audrey Kauffmann, Christelle Stamm, Zhi Chen, Yun Zhang, Vincent Bordas, Mickael Le Douget, Moriko Ito, Fang Li, John Monahan, Alex Gaither, Jason Borawski, Christopher J. Wilson, Kavitha Venkatesan, Thomas Bruemmendorf, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C193.
https://doi.org/10.1158/1535-7163.TARG-11-C193
Published: 12 November 2011
View article titled, Abstract C193: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a novel orally bioavailable, selective, and potent FGFR inhibitor.
Journal Articles

Abstract PL02-01: Targeting the PI3K pathway in cancer

William R. Sellers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): PL02-01.
https://doi.org/10.1158/1535-7163.TARG-09-PL02-01
Published: 10 December 2009
View article titled, Abstract PL02-01: Targeting the PI3K pathway in cancer